Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4396-4403

  Wenham, Robert M ^a   Schildkraut, Joellen M ^a   McLean, Kia ^a   Calingaert, Brian ^a   Bentley, Rex C ^a   Marks, Jeffrey ^a   Berchuck, Andrew ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER INVASION; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; DNA; DNA MUTATIONAL ANALYSIS; ETHNIC GROUPS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NORTH CAROLINA; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0141925969     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Whittemore, A. S., Gong, G., and Itnyre, J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U. S. population-based case-control studies of ovarian cancer. Am. J. Hum. Genet., 60: 496-504, 1997.
2. Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., and Tucker, M. A. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med., 336: 1401-1408, 1997.
3. Risch, H. A., McLaughlin, J. R., Cole, D. E., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L., Fan, I., Wong, B., and Narod, S. A. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet., 68: 700-710, 2001.
4. Szabo, C. I., and King, M. C. Invited Editorial: Population genetics of BRCA1 and BRCA2. Am. J. Hum. Genet., 60: 1013-1020, 1997.
5. Eisen, A., Rebbeck, T. R., Wood, W. C., and Weber, B. L. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J. Clin. Oncol., 18: 1980-1995, 2000.
6. Boyd, J., and Rubin, S. C. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol. Oncol., 64: 196-206, 1997.
7. Berchuck, A., Schildkraut, J. M., Marks, J. R., and Futreal, P. A. Managing hereditary ovarian cancer risk. Cancer (Phila.), 86: 2517-2524, 1999.
8. Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., Antman, K., Russo, D., Wood, M. E., Mullineau, L., Isaacs, C., Peshkin, B., Buys, S., Venne, V., Rowley, P. T., Loader, S., Offit, K., Robson, M., Hampel, H., Brener, D., Winer, E. P., Clark, S., Weber, B., Strong, L. C., and Thomas, A. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J. Clin. Oncol., 16: 2417-2425, 1998.
9. Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., and Hemminki, K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med., 343: 78-85, 2000.
10. Healey, C. S., Dunning, A. M., Teare, M. D., Chase, D., Parker, L., Burn, J., Chang-Claude, J., Mannermaa, A., Kataja, V., Huntsman, D. G., Pharoah, P. D., Luben, R. N., Easton, D. F., and Ponder, B. A. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat. Genet., 26: 362-364, 2000.
11. Spurdle, A. B., Hopper, J. L., Chen, X., Dite, G. S., Cui, J., McCredie, M. R., Giles, G. G., Ellis-Steinborner, S., Venter, D. J., Newman, B., Southey, M. C., and Chenevix-Trench, G. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol. Biomark. Prev., 11: 413-416, 2002.
12. Auranen, A., Spurdle, A. B., Chen, X., Lipscombe, J., Purdie, D. M., Hopper, J. L., Green, A., Healey, C. S., Redman, K., Dunning, A. M., Pharoah, P. D., Easton, D. F., Ponder, B. A., Chenevix-Trench, G., and Novik, K. L. BRCA2 Arg372His polymorphism and epithelial ovarian cancer risk. Int. J. Cancer, 103: 427-430, 2003.
13. Durocher, F., Shattuck-Eidens, D., McClure, M., Labrie, F., Skolnick, M. H., Goldgar, D. E., and Simard, J. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum. Mol. Genet., 5: 835-842, 1996.
14. Dunning, A. M., Chiano, M., Smith, N. R., Dearden, J., Gore, M., Oakes, S., Wilson, C., Stratton, M., Peto, J., Easton, D., Clayton, D., and Ponder, B. A. Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum. Mol. Genet., 6: 285-289, 1997.
15. Janezic, S. A., Ziogas, A., Krumroy, L. M., Krasner, M., Plummer, S. J., Cohen, P., Gildea, M., Barker, D., Haile, R., Casey, G., and Anton-Culver, H. Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum. Mol. Genet., 8: 889-897, 1999.
16. Smith, S. A., Richards, W. E., Caito, K., Hanjani, P., Markman, M., DeGeest, K., and Gallion, H. H. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecol. Oncol. Group study. Gynecol. Oncol., 83: 586-592, 2001.
17. McKenna, N. J., Kieback, D. G., Carney, D. N., Fanning, M., McLinden, J., and Headon, D. R. A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. Br. J. Cancer, 71: 451-455, 1995.
18. Rowe, S. M., Coughlan, S. J., McKenna, N. J., Garrett, E., Kieback, D. G., Carney, D. N., and Headon, D. R. Ovarian carcinoma-associated TaqI restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res., 55: 2743-2745, 1995.
19. Spurdle, A. B., Webb, P. M., Purdie, D. M., Chen, X., Green, A., and Chenevix-Trench, G. No significant association between progesterone receptor exon 4 Va1660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis (Lond.), 22: 717-721, 2001.
20. Spurdle, A. B., Webb, P. M., Chen, X., Martin, N. G., Giles, G. G., Hopper, J. L., and Chenevix-Trench, G. Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer. Int. J. Cancer, 87: 637-643, 2000.
21. Levine, D. A., and Boyd, J. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res., 61: 908-911, 2001.
22. Garner, E. I., Stokes, E. E., Berkowitz, R. S., Mok, S. C., and Cramer, D. W. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res., 62: 3058-3062, 2002.
23. Spurdle, A. B., Chen, X., Abbazadegan, M., Martin, N., Khoo, S. K., Hurst, T., Ward, B., Webb, P. M., and Chenevix-Trench, G. CYP17 promotor polymorphism and ovarian cancer risk. Int. J. Cancer, 86: 436-439, 2000.
24. Runnebaum, I. B., Tong, X. W., Konig, R., Zhao, H., Korner, K., Atkinson, E. N., Kreienberg, R., Kieback, D. G., and Hong, Z. c. t. Z. H. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet, 345: 994, 1995.
25. Lancaster, J. M., Brownlee, H. A., Wiseman, R. W., and Taylor, J. p53 polymorphism in ovarian and bladder cancer. Lancet, 346: 182, 1995.
26. Lancaster, J. M., Taylor, J. A., Brownlee, H. A., Bell, D. A., Berchuck, A., and Wiseman, R. W. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol. Carcinog., 17: 160-162, 1996.
27. Spurdle, A. B., Purdie, D. M., Webb, P. M., Chen, X., Green, A., and Chenevix-Trench, G. The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer. Mol. Carcinog., 30: 71-78, 2001.
28. Thomas, D. C., and Witte, J. S. Point: population stratification: a problem for case-control studies of candidate-gene associations? Cancer Epidemiol. Biomark. Prev., 11: 505-512, 2002.
29. Colombo, N., Sessa, C., Landoni, F., Sartori, E., Pecorelli, S., and Mangioni, C. Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary. Obstet. Gynecol., 67: 265-268, 1986.
30. Weiss, N. S., and Peterson, A. S. Racial variation in the incidence of ovarian cancer in the United States. Am. J. Epidemiol., 107: 91-95, 1978.